Vein occlusion is 3rd opportunity....primary focus is AMD.
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-31
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.0¢ |
Change
0.015(1.91%) |
Mkt cap ! $966.4M | |||
| Open | High | Low | Value | Volume |
| 78.5¢ | 80.5¢ | 78.5¢ | $92.18K | 116.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4564 | 80.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.5¢ | 14740 | 7 |
View Market Depth
| Last trade - 10.36am 08/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |